UBS Maintains a 'Buy' on McKesson (MCK); Blowout F2Q12
Tweet
Share
E-mailGet Alerts MCK Hot Sheet
Price: $858.90 +2.40%
Rating Summary:
21 Buy, 9 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
21 Buy, 9 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
UBS maintains a 'Buy' on McKesson (NYSE: MCK) price target raised $3.00 to $99.00.
UBS analyst says, "MCK and Drug Distributor Momentum Continues With Blowout Qtr: We believe the MCK F2Q12 EPS simply could not have been much better than what the company just reported, with 27% adjusted EPS growth fueled by 17% growth in core drug distribution EBIT, and 26% growth in the technology segment. With buybacks, this translated into $1.63 EPS that easily beat both UBS/Street’s $1.40."
"Despite the big beat in F2Q12, mgmt raised its full-year F2012 EPS guidance range by $0.10 to $6.19-6.39. Our sense is that MCK is simply continuing to be conservative, and we raise our F2012 EPS estimate slightly above the new guidance range from $6.22 to $6.40. With megasized generic-exclusivity launches coming up over the next two quarters, it seems likely to us that MCK will exceed its newly increased guidance. We also raise F2013 estimate from $7.07 to $7.25 (which includes VA)."
For more ratings news on McKesson click here and for the rating history of McKesson click here.
Shares of McKesson closed at $76.13 yesterday.
UBS analyst says, "MCK and Drug Distributor Momentum Continues With Blowout Qtr: We believe the MCK F2Q12 EPS simply could not have been much better than what the company just reported, with 27% adjusted EPS growth fueled by 17% growth in core drug distribution EBIT, and 26% growth in the technology segment. With buybacks, this translated into $1.63 EPS that easily beat both UBS/Street’s $1.40."
"Despite the big beat in F2Q12, mgmt raised its full-year F2012 EPS guidance range by $0.10 to $6.19-6.39. Our sense is that MCK is simply continuing to be conservative, and we raise our F2012 EPS estimate slightly above the new guidance range from $6.22 to $6.40. With megasized generic-exclusivity launches coming up over the next two quarters, it seems likely to us that MCK will exceed its newly increased guidance. We also raise F2013 estimate from $7.07 to $7.25 (which includes VA)."
For more ratings news on McKesson click here and for the rating history of McKesson click here.
Shares of McKesson closed at $76.13 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- McKesson (MCK) PT Raised to $1,000 at Barclays
- Rockwell Automation (ROK) PT Lowered to $490 at DA Davidson
- Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
UBSSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
